期刊文献+

41例儿童慢性乙型肝炎患者抗病毒药物使用分析 被引量:3

Analysis of Utilization of Anti-HBV Drugs in 41 Cases Children with Chronic Hepatitis B
下载PDF
导出
摘要 目的:分析我院儿童慢性乙型肝炎(乙肝)抗病毒药物使用情况,为临床合理用药提供参考。方法:选取2014年5月~2015年7月在我院进行慢性乙肝抗病毒治疗持续时间>1年的患儿,对初始药物选择、开始在我院抗病毒时的年龄分布、超说明书使用情况以及治疗期间HBV-DNA改变情况等进行统计分析。结果:41例儿童慢性乙肝患者抗病毒用药选择中,开始治疗选择拉米夫定的占36.58%,但其中66.67%的患儿1年内调整了抗病毒药物;拉米夫定、阿德福韦酯、恩替卡韦、替比夫定等药品使用中都存在超说明书用药情况。结论:儿童抗病毒用药不宜首选拉米夫定,儿童用药需要进行规范化管理,及时进行相关临床试验以更新说明书关于儿童用药的部分,保证儿童患者的用药安全。 Objective: To investigate the utilization of anti-HBV drugs in children with chronic hepatitis B,in order to guide the clinical rational drug use. Methods: The children were chosen from May 2014 to July 2015 in our hospital,more than one years of continuous treatment. The age distribution of antiviral drugs used in our hospital. The initial drug selection began in our hospital,off-label drug use in children and HBV-DNA changes during the treatment period were analyzed. Results: Among the antiviral treatment for 41 cases children with chronic hepatitis B,the most options for children were lamivudine at first,accounted for 36. 58%. But one year adjustment of antiviral drugs accounted for 66. 67%; The situation exists in the use of ultra manual by lamivudine,adefovir,entecavir and telbivudine. Conclusion: Children with antiviral drugs should not be preferred lamivudine. For the safety use of drugs in children,standardized management was urgently needed,clinical trials of pediatric pharmacology should be done to update the information of drug labels.
出处 《药物流行病学杂志》 CAS 2017年第1期53-55,共3页 Chinese Journal of Pharmacoepidemiology
关键词 儿童 乙型肝炎 慢性 抗病毒药物 合理用药 Children Hepatitis B chronic Antiviral drugs Rational drug use
  • 引文网络
  • 相关文献

参考文献4

二级参考文献53

  • 1Lai CL,Shouval D,Lok AS,陈楠(摘译),张占卿(审校).恩替卡韦与拉米夫定治疗HBeAg阴性慢性乙型肝炎的对照研究[J].世界感染杂志,2006,6(4):396-396. 被引量:201
  • 2张鸿飞,朱世殊,杨晓晋,徐志强,董漪,陈大为,赵景民,陈菊梅,张太和.小儿乙、丙型肝炎临床与病理研究[J].传染病信息,2006,19(3):130-131. 被引量:25
  • 3Sokal EM, Roberts EA, Mieli-Vergani G, et al.A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B[J].Antimicrob Agents Chemother,2000,44(3):590.
  • 4Sokal EM,Bortolotti F. Update on prevention and treatment of viral hepatitis in children[J].Curr Opin Pediatr, 1999,11(5):384.
  • 5Da Silva LC, Pinho JR, Sitnik R, et al. Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B[J].J Gastroenterol,2001,36(7):476.
  • 6Zuccotti GV,Cucchi C,Gracchi V,et al.A 1-year trial of lamivudine for chronic hepatitis B in children[J]J I nt Med Res, 2002,30(2):200.
  • 7Jonas MM,Kelley DA,Mizerski J,et al. Clinical trial of lamivudine in children with chronic hepatitis B[J]J Hepatol,2003,38(5):698.
  • 8European Association for the Study of the Liver. EASL clinical practice guidelines : management of chronic hepatitis B virus in- fection[J]. J Hepatol,2012,57:167-185.
  • 9Jonas MM, Block JM , Haber BA, et al. Treatment of children with chronic hepatitis B virus infection in the United States : pa- tient selection and therapeutic options [J]. Hepatology, 2010, 52(6) : 2192-2205.
  • 10Sokal EM, Paganelli M, Wirth S, et al. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guide- lines consensus of an expert panel on behalf of the European So- ciety of Pediatric Gastroenterology, Hepatology and Nutri- tionF.l]. J Henatol, 2013, 59:814-829.

共引文献808

同被引文献47

引证文献3

二级引证文献13

;
使用帮助 返回顶部